Literature DB >> 26223270

Depression in multiple sclerosis: The utility of common self-report instruments and development of a disease-specific measure.

Lauren B Strober1, Peter A Arnett.   

Abstract

The ultimate objective of the present investigation was to improve the detection of depression in multiple sclerosis (MS) by comparing common self-report depression measures to a new, modified measure, which takes into account the contribution that symptoms of MS may have on individuals' reports. There has been a longstanding concern regarding the accurate assessment of depression in MS, particularly with regard to the overlap of MS symptomatology and neurovegetative depression symptoms on self-report questionnaires, which may lead to an overdiagnosis of depression in MS. To address these difficulties, we previously proposed a "trunk and branch" of depression in MS. This model allows for the delineation of what symptoms are most reflective of depression in MS. By identifying these symptoms, it was possible to develop a modified Beck Depression Inventory (BDI) in which only the items found to be most related to depression in MS are included in the new measure, the MS Specific BDI (MS-BDI). We compared this measure to common self-report instruments (Beck Depression Inventory-Second Edition, BDI-II; Beck Depression Inventory-Fast Screen, BDI-FS; Chicago Multiscale Depression Inventory, CMDI). Results suggest that cutoffs of 4 on the BDI-FS and 23 on the CMDI Mood subscale are most useful when screening for depression in MS, with a sensitivity for both of 100%, while a cutoff of 19 on the BDI-II, a cutoff of 22 on the CMDI Evaluative scale, and a cutoff of 8 on the MS-BDI had high specificities, suggesting they can be used as to assist in diagnosing depression in MS.

Entities:  

Keywords:  Assessment; Beck Depression Inventory; Depression; Multiple sclerosis; Self-report

Mesh:

Year:  2015        PMID: 26223270     DOI: 10.1080/13803395.2015.1063591

Source DB:  PubMed          Journal:  J Clin Exp Neuropsychol        ISSN: 1380-3395            Impact factor:   2.475


  8 in total

Review 1.  Psychiatric disorders in multiple sclerosis.

Authors:  Maddalena Sparaco; Luigi Lavorgna; Simona Bonavita
Journal:  J Neurol       Date:  2019-06-13       Impact factor: 4.849

Review 2.  Mental Health Comorbidity in MS: Depression, Anxiety, and Bipolar Disorder.

Authors:  Aaron P Turner; Kevin N Alschuler; Abbey J Hughes; Meghan Beier; Jodie K Haselkorn; Alicia P Sloan; Dawn M Ehde
Journal:  Curr Neurol Neurosci Rep       Date:  2016-12       Impact factor: 5.081

3.  Anxiety and depression in Multiple Sclerosis (MS): Antecedents, consequences, and differential impact on well-being and quality of life.

Authors:  Mariam Hanna; Lauren Beth Strober
Journal:  Mult Scler Relat Disord       Date:  2020-06-06       Impact factor: 4.339

Review 4.  The manifestation of affective symptoms in multiple sclerosis and discussion of the currently available diagnostic assessment tools.

Authors:  Melanie Filser; Axel Buchner; Gereon Rudolf Fink; Stefan M Gold; Iris-Katharina Penner
Journal:  J Neurol       Date:  2022-09-21       Impact factor: 6.682

Review 5.  How depressed is "depressed"? A systematic review and diagnostic meta-analysis of optimal cut points for the Beck Depression Inventory revised (BDI-II).

Authors:  Michael von Glischinski; Ruth von Brachel; Gerrit Hirschfeld
Journal:  Qual Life Res       Date:  2018-11-19       Impact factor: 4.147

6.  Aerobic reserve capacity in multiple sclerosis-Preliminary evidence.

Authors:  Corey D Feasel; Brian M Sandroff; Robert W Motl
Journal:  Acta Neurol Scand       Date:  2021-04-29       Impact factor: 3.915

7.  Neural Correlates of Outcome Anticipation in Multiple Sclerosis.

Authors:  Angela Spirou; Pei-Pei Liu; Joman Y Natsheh; Eliane Neuteboom; Ekaterina Dobryakova
Journal:  Front Neurol       Date:  2018-07-25       Impact factor: 4.003

8.  Transdiagnostic treatment of emotional disorders for women with multiple sclerosis: a randomized controlled trial.

Authors:  Nabi Nazari; Akram Aligholipour; Masoud Sadeghi
Journal:  BMC Womens Health       Date:  2020-10-31       Impact factor: 2.809

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.